GO:1904408 melatonin binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904408 (melatonin binding) is a molecular function defined as binding to melatonin, the pineal hormone that regulates circadian and seasonal rhythms.
• Melatonin binding is mediated by high-affinity G-protein-coupled receptors MT1 and MT2, the nuclear receptor ROR/RZR family, and the enzyme NQO2 (MT3) [1,3,5].
• The vitamin D receptor (VDR) has been identified as a novel melatonin-binding nuclear receptor, expanding the known melatonin interactome.
• Melatonin binding sites were first characterized pharmacologically in the 1980s using radioligand assays, establishing the foundation for modern receptor pharmacology [2,7].
• Dysregulated melatonin binding is implicated in circadian rhythm disorders, seasonal reproduction, cancer, and neurodegenerative disease [4,6].
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential for dissecting the causal roles of melatonin-binding proteins in physiology and disease [1,3,8].
Description
Melatonin binding (GO:1904408) is the molecular function of selectively and non-covalently interacting with melatonin, an indoleamine hormone synthesized primarily by the pineal gland. This function is the first step in melatonin signal transduction and is essential for translating the hormonal message into cellular responses that regulate circadian rhythms, sleep, seasonal reproduction, and antioxidant defense [2,4]. The existence of specific melatonin binding sites was first demonstrated by radioligand binding studies in the late 1980s, which revealed high-affinity, saturable, and reversible binding in brain and peripheral tissues [2,7]. Since then, molecular cloning and pharmacological characterization have identified several distinct melatonin-binding proteins, including the G-protein-coupled receptors MT1 (MTNR1A) and MT2 (MTNR1B), the cytosolic enzyme NQO2 (also known as MT3), and nuclear receptors of the ROR/RZR family [1,3,5]. More recently, the vitamin D receptor (VDR) was identified as a novel melatonin-binding nuclear receptor, suggesting that melatonin's actions extend beyond classical membrane signaling. Understanding the molecular details of melatonin binding is critical for drug discovery, as receptor subtype-selective ligands are being developed for insomnia, circadian rhythm disorders, and cancer. This article provides a research-grade overview of GO:1904408, covering its definition, mechanism, key genes, disease relevance, and the CRISPR-based models and methods used to study it.
melatonin binding At A Glance
| GO ID | GO:1904408 |
|---|---|
| GO term | melatonin binding |
| Ontology | molecular_function |
| Synonym | none |
| Definition | Binding to melatonin. |
| Major function | Selective non-covalent interaction with melatonin, initiating signaling or metabolic effects. |
| Key binding proteins | MTNR1A (MT1), MTNR1B (MT2), NQO2 (MT3), ROR/RZR, VDR |
| Cellular locations | Plasma membrane, cytoplasm, nucleus |
| Related diseases | Circadian rhythm disorders, insomnia, seasonal affective disorder, cancer, neurodegeneration |
What Is GO:1904408?
According to the Gene Ontology, GO:1904408 (melatonin binding) is defined as the molecular function of binding to melatonin. In practical terms, it describes the ability of a protein or macromolecular complex to recognize and physically associate with melatonin through non-covalent interactions, such as hydrogen bonding, hydrophobic contacts, and van der Waals forces. This binding event is the initial step in melatonin signaling and can occur at the cell surface (e.g., MT1/MT2 receptors), in the cytoplasm (e.g., NQO2/MT3), or in the nucleus (e.g., ROR/RZR, VDR) [1,3,5,8]. The term is classified under molecular_function and does not imply any downstream signaling or physiological outcome by itself; rather, it captures the selective interaction with the ligand melatonin.
Why Is melatonin binding Important in Cell Biology?
Melatonin binding is the molecular gateway for one of the most ancient and conserved hormonal signaling systems in biology. It governs daily and seasonal rhythms, influences sleep architecture, modulates immune function, and protects against oxidative stress [2,4]. Pharmacologically, melatonin-binding proteins are validated drug targets; for example, MT1/MT2 agonists such as ramelteon and tasimelteon are approved for insomnia and non-24-hour sleep-wake disorder, while MT3 (NQO2) ligands are being explored for cancer and neuroprotection [3,5,6]. Moreover, the discovery of VDR as a melatonin-binding nuclear receptor links melatonin to vitamin D signaling and broader nuclear hormone networks. Consequently, understanding the structural and functional basis of melatonin binding is essential for developing subtype-selective therapeutics and for interpreting genetic variants associated with circadian and metabolic phenotypes.
• Melatonin binding initiates circadian rhythm regulation, affecting sleep-wake cycles and seasonal reproduction [2,4].
• MT1 and MT2 receptors are targets for approved drugs treating insomnia and circadian rhythm disorders [1,6].
• NQO2 (MT3) binding modulates quinone reductase activity and may influence cancer cell survival [3,5].
• VDR-mediated melatonin binding connects melatonin to vitamin D signaling and nuclear receptor networks.
• Melatonin binding sites are implicated in neuroprotection, antioxidant defense, and immune modulation.
• Altered melatonin binding is associated with seasonal affective disorder, jet lag, and shift work disorders.
• Melatonin-binding proteins are potential biomarkers and therapeutic targets in breast, prostate, and colorectal cancers [5,6].
• Genetic variants in MTNR1B are linked to type 2 diabetes and impaired glucose tolerance.
• CRISPR-based models of melatonin-binding genes enable causal dissection of circadian and metabolic phenotypes [1,8].
• Understanding melatonin binding at atomic resolution facilitates rational design of subtype-selective ligands.
Molecular Mechanism of melatonin binding
Ligand recognition and binding pocket architecture
In simple terms: Melatonin fits into a specific pocket in its receptor proteins, like a key in a lock.
Melatonin binding is initiated by the recognition of the indoleamine scaffold by a complementary binding pocket. In MT1 and MT2 receptors, the binding site is located within the transmembrane helical bundle, where residues in helices III, V, and VI form hydrogen bonds with the methoxy and acetamide groups of melatonin, while aromatic residues provide hydrophobic contacts. In NQO2 (MT3), the binding pocket is more solvent-exposed and accommodates melatonin in a distinct orientation compared to classical quinone substrates [3,5]. The vitamin D receptor binds melatonin through a nuclear receptor ligand-binding domain, although the exact structural determinants remain to be fully elucidated. These diverse binding modes explain the wide range of melatonin affinities and selectivities observed across protein families.
Conformational changes and receptor activation
In simple terms: When melatonin binds, the receptor changes shape to trigger a signal inside the cell.
For G-protein-coupled MT1 and MT2 receptors, melatonin binding induces conformational rearrangements in the transmembrane helices, particularly in helix VI, which opens a cavity for G-protein coupling. This activation leads to the exchange of GDP for GTP on Gαi/o subunits, inhibiting adenylyl cyclase and reducing cAMP levels. Biophysical simulations and experimental evidence have revealed that potent melatonin receptor ligands can stabilize distinct active and inactive states, and the kinetics of binding and unbinding are critical for efficacy. In contrast, NQO2 (MT3) does not signal through G-proteins; instead, melatonin binding modulates its enzymatic activity as a quinone reductase, potentially altering cellular redox balance [3,5].
Cofactors and allosteric modulation
In simple terms: Some helper molecules and other proteins can change how well melatonin binds.
Melatonin binding to NQO2 requires the presence of a cofactor, typically FAD, which is essential for the enzyme's structural integrity and catalytic activity. In MT1 and MT2 receptors, sodium ions and cholesterol molecules can act as allosteric modulators, influencing ligand binding affinity and receptor stability. Additionally, heterodimerization between MT1 and MT2, or with other GPCRs, can alter binding pharmacology and signaling outcomes. These cofactors and allosteric interactions add layers of regulation that are important for drug design and for understanding tissue-specific responses to melatonin.
Binding kinetics and reversibility
In simple terms: Melatonin attaches and detaches from its targets at different speeds, which affects how long the signal lasts.
Melatonin binding is reversible and governed by association (kon) and dissociation (koff) rate constants. Radioligand binding studies have determined that MT1 and MT2 receptors exhibit high affinity (low nanomolar Kd) for melatonin, whereas NQO2 (MT3) has lower affinity (micromolar range) [2,5]. Recent mechanistic simulations combined with experimental evidence have shown that the unbinding of potent ligands can be extremely slow, leading to long receptor occupancy and prolonged signaling. These kinetic parameters are critical for predicting the duration of action of melatonin-based therapeutics and for understanding physiological responses to the nocturnal melatonin surge.
Key Genes Involved in GO:1904408 melatonin binding
The following genes encode proteins that directly bind melatonin or are closely associated with melatonin-binding complexes, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MTNR1A | Encodes MT1 melatonin receptor, a G-protein-coupled receptor that binds melatonin with high affinity and inhibits cAMP. | Target for insomnia and circadian rhythm drugs; knockout models show altered sleep and metabolic phenotypes. |
| MTNR1B | Encodes MT2 melatonin receptor, another GPCR that binds melatonin and regulates phase shifting and glucose homeostasis. | Genetic variants linked to type 2 diabetes; knockout and knock-in models used to study glucose metabolism. |
| NQO2 | Encodes quinone reductase 2 (MT3), a cytosolic enzyme that binds melatonin and modulates redox balance [3,5]. | Potential target in cancer and neuroprotection; binding assays and knockout models available [3,5]. |
| VDR | Encodes vitamin D receptor, a nuclear receptor recently identified as a melatonin-binding protein. | Links melatonin to vitamin D signaling; knockout and overexpression models exist for studying nuclear actions. |
| RORA | Encodes RORα, a nuclear receptor that binds melatonin and regulates circadian gene expression. | Implicated in circadian rhythm and cancer; knockout mice show circadian abnormalities. |
| RORB | Encodes RORβ, a nuclear receptor with affinity for melatonin, involved in retinal and pineal function. | Studied in seasonal reproduction and retinal degeneration models. |
| RORC | Encodes RORγ, a nuclear receptor that can bind melatonin and regulates immune and metabolic genes. | Target in autoimmune and metabolic diseases; knockout models available. |
| GNAI1 | Encodes Gαi1 subunit that couples to MT1/MT2 upon melatonin binding. | Knockout and point-mutation models used to dissect GPCR signaling. |
| GNAI2 | Encodes Gαi2 subunit involved in melatonin receptor signaling. | Relevant to circadian and immune regulation; conditional knockouts exist. |
| GNAI3 | Encodes Gαi3 subunit that participates in melatonin receptor-mediated inhibition of adenylyl cyclase. | Used in studies of GPCR specificity and signaling bias. |
| ARRB1 | Encodes β-arrestin 1, which regulates desensitization and internalization of melatonin receptors. | Knockout models reveal roles in receptor trafficking and signaling. |
| ARRB2 | Encodes β-arrestin 2, another regulator of melatonin receptor desensitization. | Implicated in GPCR biased signaling; knockout and overexpression models available. |
| PRKACA | Encodes catalytic subunit of PKA, a downstream effector inhibited by melatonin binding to MT1/MT2. | Used to study cAMP-dependent pathways in circadian clocks. |
| CREB1 | Encodes CREB, a transcription factor modulated by melatonin signaling. | Knockout and phospho-mutant models for circadian gene regulation. |
| PER1 | Encodes Period circadian protein 1, a core clock gene regulated by melatonin binding. | Knockout models show altered circadian rhythms and metabolism. |
| PER2 | Encodes Period circadian protein 2, another core clock component influenced by melatonin. | Mutant models used in sleep and metabolic studies. |
| CLOCK | Encodes CLOCK, a master circadian transcription factor that interacts with melatonin signaling. | Knockout and point-mutation models for circadian and metabolic phenotyping. |
| ARNTL | Encodes BMAL1, the heterodimeric partner of CLOCK, regulated by melatonin binding. | Conditional knockout models for tissue-specific clock function. |
How Is melatonin binding Regulated?
Melatonin binding is regulated at multiple levels. Receptor expression and availability are controlled by circadian clock genes, light exposure, and hormonal feedback. For example, MT1 and MT2 receptor densities fluctuate across the day-night cycle, and prolonged melatonin exposure leads to receptor desensitization via β-arrestin recruitment and internalization. Allosteric modulators such as sodium ions and cholesterol can alter binding affinity. In the case of NQO2 (MT3), binding is influenced by the redox state of the cell and the availability of FAD cofactor. Additionally, post-translational modifications of melatonin-binding proteins, such as phosphorylation, can modulate their ligand affinity or subcellular localization. These regulatory mechanisms ensure that melatonin responses are temporally and spatially appropriate.
melatonin binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MTNR1A | Insomnia, circadian rhythm sleep disorders | Knockout mouse, point-mutation knock-in for ligand binding residues |
| MTNR1B | Type 2 diabetes, impaired glucose tolerance | Knockout and humanized knock-in models; overexpression in pancreatic beta cells |
| NQO2 | Cancer chemoresistance, oxidative stress | Knockout and point-mutation models; overexpression for drug screening |
| VDR | Neurodegeneration, vitamin D-related disorders | Knockout and tagged knock-in for nuclear binding studies |
| RORA | Circadian rhythm disorders, cancer | Knockout and overexpression models for circadian phenotyping |
Circadian rhythm and sleep disorders
Melatonin binding is central to the regulation of circadian rhythms, and disruptions in this function are associated with insomnia, delayed sleep phase disorder, and shift work disorder [1,4]. MT1 and MT2 receptor agonists such as ramelteon and tasimelteon are approved for these conditions, highlighting the clinical relevance of melatonin binding. Genetic variants in MTNR1B have been linked to altered glucose tolerance and type 2 diabetes risk, further emphasizing the metabolic impact of melatonin signaling.
Cancer
Melatonin binding to MT1, MT2, and NQO2 (MT3) has been implicated in cancer biology. Melatonin exerts oncostatic effects in breast, prostate, and colorectal cancers, partly through MT1-mediated inhibition of cAMP and downstream proliferative pathways [5,6]. NQO2 (MT3) binding modulates quinone reductase activity, which can influence oxidative stress and chemoresistance [3,5]. Targeting melatonin-binding proteins is therefore a potential therapeutic strategy in oncology.
Neurodegeneration and neuroprotection
Melatonin binding sites in the brain are involved in neuroprotective effects against oxidative stress and amyloid-beta toxicity. MT1 and MT2 receptors mediate melatonin's antioxidant and anti-inflammatory actions in models of Alzheimer's and Parkinson's diseases. The nuclear receptor VDR, recently identified as a melatonin-binding protein, may link melatonin to vitamin D-mediated neuroprotection. These findings suggest that modulating melatonin binding could be beneficial in neurodegenerative disorders.
Seasonal reproduction and metabolic disorders
Melatonin binding sites in the hypothalamus and pituitary regulate seasonal reproduction in photoperiodic animals. In humans, melatonin binding influences metabolic parameters such as insulin sensitivity and glucose homeostasis, with MTNR1B variants associated with type 2 diabetes. Understanding these pathways may lead to new interventions for metabolic syndrome and reproductive disorders.
From melatonin binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does MT1 receptor mediate melatonin-induced sleep promotion? | MTNR1A knockout mouse |
| What is the role of a specific binding pocket residue in MT2? | Point-mutation knock-in of MTNR1B in cell lines |
| How does NQO2 (MT3) contribute to chemoresistance? | NQO2 knockout cancer cell lines and xenografts |
| Does VDR mediate nuclear melatonin signaling? | VDR knockout and tagged knock-in models |
| Can overexpression of MT1 enhance melatonin sensitivity? | MTNR1A overexpression in neuronal cell lines |
| What are the downstream targets of melatonin binding in the clock? | CRISPR knockout of PER1/PER2 combined with RNA-seq |
How to Study the melatonin binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding assay | Affinity (Kd) and density (Bmax) of melatonin binding sites | Characterizing MT1/MT2/MT3 in tissues and cell lines [2,5] |
| Isothermal titration calorimetry | Thermodynamics of melatonin-protein interaction | Measuring binding to NQO2 and other purified proteins |
| Molecular dynamics simulation | Binding pose, conformational changes, unbinding kinetics | Rational drug design for melatonin receptor ligands |
| CRISPR knockout screening | Genes required for melatonin binding or signaling | Discovery of novel pathway components |
| RNA-seq | Transcriptional changes upon melatonin binding | Identifying downstream target genes in clock and cancer cells |
| Proteomics | Protein interaction partners of melatonin-binding proteins | Mapping the melatonin interactome |
| Live-cell imaging | Receptor internalization and trafficking | Studying desensitization of MT1/MT2 |
| Electrophysiology | Ion channel modulation by melatonin binding | Neuronal excitability studies |
Radioligand binding assays
Radioligand binding assays using 2-[125I]iodomelatonin are the gold standard for measuring melatonin binding affinity (Kd) and density (Bmax) in tissues and cell membranes [2,7]. These assays can distinguish high-affinity MT1/MT2 binding from lower-affinity MT3 (NQO2) binding and are used to characterize novel ligands.
Isothermal titration calorimetry (ITC)
ITC measures the heat released or absorbed upon melatonin binding, providing thermodynamic parameters such as dissociation constant (Kd), enthalpy, and entropy. This label-free method has been applied to study melatonin binding to human NQO2 and other proteins.
Molecular dynamics simulations
Computational simulations of melatonin-receptor complexes reveal binding poses, conformational changes, and unbinding pathways at atomic resolution. These methods complement experimental binding data and guide the design of subtype-selective ligands.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that modulate melatonin binding or downstream signaling. Such screens are useful for discovering novel components of the melatonin pathway and for validating candidate targets.
How CRISPR Can Be Used to Study GO:1904408 melatonin binding
Knockout
CRISPR knockout of melatonin-binding genes such as MTNR1A, MTNR1B, NQO2, and VDR allows researchers to abolish protein function and assess the consequences for circadian rhythms, metabolism, and disease phenotypes [1,3,8]. Knockout cell lines and animal models are essential for validating drug targets and for distinguishing receptor subtypes.
Point Mutation
Point mutations can be introduced into the melatonin-binding pocket to dissect the contribution of specific residues to ligand affinity and selectivity. For example, mutating hydrogen-bonding residues in MT1 or MT2 can reduce melatonin binding and alter signaling, providing structure-function insights [1,6].
Knock-in
Knock-in models, such as tagged receptors or humanized alleles, enable visualization and biochemical purification of melatonin-binding proteins. Tagged knock-in of MTNR1A or VDR allows tracking of receptor localization and interaction partners in vivo [1,8].
Overexpression
Overexpression of melatonin-binding proteins in cell lines or transgenic animals can enhance melatonin sensitivity and amplify downstream signaling. This approach is useful for drug screening and for studying gain-of-function effects in cancer and metabolic models [1,5].
How EDITGENE Supports melatonin binding Research
Researchers studying melatonin binding-related genes often need to determine whether a candidate gene is causally involved in circadian, metabolic, or oncogenic phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous functional validation of melatonin-binding proteins and their signaling pathways.
Contact EDITGENE today to design your custom CRISPR model for melatonin binding research.
Frequently Asked Questions About melatonin binding
What is GO:1904408?
GO:1904408 is the Gene Ontology molecular function term for melatonin binding, defined as the selective non-covalent interaction with the hormone melatonin.
What genes are involved in melatonin binding?
Key genes include MTNR1A (MT1), MTNR1B (MT2), NQO2 (MT3), VDR, and RORA/RORB/RORC, which encode proteins that bind melatonin [1,3,5,8].
What is the function of melatonin binding?
Melatonin binding initiates signaling that regulates circadian rhythms, sleep, seasonal reproduction, antioxidant defense, and metabolism [1,4].
Which receptors bind melatonin?
Melatonin binds to G-protein-coupled receptors MT1 and MT2, the cytosolic enzyme NQO2 (MT3), nuclear receptors ROR/RZR, and the vitamin D receptor (VDR) [1,3,5,8].
How is melatonin binding measured?
Common methods include radioligand binding assays with 2-[125I]iodomelatonin, isothermal titration calorimetry, and molecular dynamics simulations [2,3,6].
What diseases are associated with melatonin binding?
Disorders include insomnia, circadian rhythm sleep disorders, type 2 diabetes, cancer, and neurodegenerative diseases [1,4,5,7].
Can CRISPR be used to study melatonin binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect the roles of melatonin-binding proteins in cells and animals [1,3,8].
What is the difference between MT1, MT2, and MT3?
MT1 and MT2 are high-affinity G-protein-coupled receptors, while MT3 is a lower-affinity cytosolic binding site identified as NQO2 [1,3,5].
Is melatonin binding reversible?
Yes, melatonin binding is reversible, with dissociation kinetics that vary among receptors and ligands, influencing the duration of signaling.
How does melatonin binding affect sleep?
Melatonin binding to MT1 and MT2 receptors in the suprachiasmatic nucleus and other brain regions promotes sleep onset and phase shifts the circadian clock [1,4].
Conclusion
GO:1904408 (melatonin binding) is a fundamental molecular function that underpins the diverse physiological actions of melatonin, from circadian rhythm regulation to antioxidant defense and metabolic control. The identification of multiple melatonin-binding proteins, including MT1, MT2, NQO2 (MT3), ROR/RZR, and VDR, has revealed a complex signaling network with broad therapeutic potential [1,3,5,8]. Continued research using CRISPR-based models and advanced biophysical methods will further elucidate the structural and functional nuances of melatonin binding, paving the way for novel treatments for sleep disorders, cancer, and metabolic diseases.
References
- 1. Okamoto HH et al.. 2024. Melatonin receptor structure and signaling.. J Pineal Res 76(3):e12952 PMID: 38587234
- 2. Vanĕcek J. 1988. Melatonin binding sites.. J Neurochem 51(5):1436-40 PMID: 3171587
- 3. Calamini B et al.. 2022. Melatonin Binding to Human NQO2 by Isothermal Titration Calorimetry.. Methods Mol Biol 2550:305-314 PMID: 36180701
- 4. Kennaway DJ et al.. 1995. Melatonin binding sites and their role in seasonal reproduction.. J Reprod Fertil Suppl 49:423-35 PMID: 7623332
- 5. Legros C et al.. 2022. Measuring Binding at the Putative Melatonin Receptor MT3.. Methods Mol Biol 2550:283-289 PMID: 36180699
- 6. Bedini A et al.. 2024. Binding and unbinding of potent melatonin receptor ligands: Mechanistic simulations and experimental evidence.. J Pineal Res 76(2):e12941 PMID: 38606814
- 7. Zisapel N. 1988. Melatonin receptors revisited.. J Neural Transm 73(1):1-5 PMID: 2841420
- 8. Fang N et al.. 2020. Identification of a novel melatonin-binding nuclear receptor: Vitamin D receptor.. J Pineal Res 68(1):e12618 PMID: 31631405
